Introduction {#Sec1}
============

Suicide is one of the major causes of death worldwide, with figures suggesting that approximately 1 million people commit suicide each year \[[@CR1]\]. Although completed suicide is rare before the age of 10, suicidal behaviour increases sharply during adolescence and is a leading cause of death among young people \[[@CR2]\]. Several biological, social, and psychological risk factors for suicidality seem to be shared by children, adolescents, and adults. Suicide risk follows a multifactorial trajectory and is increased in many psychiatric disorders varying by diagnosis, gender, and age \[[@CR3]\]. The previous evidence suggests, however, that some risk factors for suicide might be different in adolescents compared with adults \[[@CR4]\]. In adolescents, it is frequent that negative life events precede suicidal behaviour, most commonly family conflicts \[[@CR5]--[@CR7]\], changes of residence \[[@CR8]\], romantic breakup \[[@CR9]\], conflict with peers, including bullying \[[@CR10], [@CR11]\], and/or academic failure \[[@CR12]\]. These differences in adolescence indicate a pressing need for the development of instruments aimed at specifically assessing protective and risk factors in young people. Considering that many of the adolescents committing suicide have never received any mental health support \[[@CR13]\] and that several interventions have shown efficacy in preventing suicidal behaviour \[[@CR14]--[@CR16]\], it is essential to develop mechanisms that enable identification of subjects at risk and promote early intervention. Since suicide is a sensitive topic, which can be associated with stigma, web-based health monitoring platforms could be especially useful tools, as they provide a space for privacy.

To date, there are few valid and reliable, and developmentally sensitive instruments for collecting comprehensive data on risk, clinical and psychosocial mediators of suicidality in paediatric populations available for use by clinicians \[[@CR17], [@CR18]\]. One of the most widely accepted screening instruments, the Columbia-Suicide Severity Rating Scale (C-SSRS), has been shown to identify accurately individuals at risk of suicide, both in adult and paediatric populations, and has been used as the gold standard for the assessment of suicidal ideation and behaviours in clinical trials \[[@CR19]\]; however, its clinical utility has been questioned \[[@CR20]\]. One reason for this is that the C-SSRS has been deemed not to be sensitive enough to be able to capture the full range of suicidal ideation or behaviour \[[@CR20]\]. The development of the STOP (Suicidality: Treatment Occurring in Paediatrics) Risk and Resilience Factors Scales has the potential to overcome this limitation by addressing the full range of suicidal ideation or behaviour whether singly or in combination.

The STOP project (Suicidality: Treatment Occurring in Paediatrics <http://cordis.europa.eu/project/rcn/97369_en.html>) was predominantly dedicated to the development of a comprehensive web-based assessment of suicidality and its mediators in children and adolescents. The aim of this specific study, which was embedded within the overall project, was to develop and assess the validity of the multi-informant STOP-Risk Factors Scale (STOP-SRiFS) and the multi-informant STOP Resilience Factors Scale (STOP-SReFS) as instruments for the collection of comprehensive data on psychosocial risk and protective factors for suicidal behaviours in the adolescent population.

Methods {#Sec2}
=======

Figure [1](#Fig1){ref-type="fig"} shows a general overview of the development and validation of the STOP-SRiFS and the STOP-SReFS. Phase 1 focused on the development of the scales and Phase 2 focused on their validation. For Phase 2---sample 1 (*n* = 87), the scales were administered to a sample of adolescents, their parents/carers, and clinicians (Fig. [1](#Fig1){ref-type="fig"}). This sample served to explore the psychometric properties of the scales (test--retest reliability). Sample 2 consisted of adolescents (*n* = 259) that completed the STOP-SRiFS and/or the STOP-SReFS scales, parents (*n* = 213) who completed one or both scales, and the young persons' clinicians (*n* = 254). The samples partially overlapped with one another. Sample 2 was used for the Exploratory Factor Analyses (EFA) and the other psychometric analyses of the scales.Fig. 1General overview of the development and validation of the STOP-Suicidality Risk Factors Scale (STOP-SRiFS) and the STOP-Suicidality Resilience Factors Scale (STOP-SReFS). *C-SSRS* Columbia-Suicide Severity Rating Scale, *EFA* exploratory factor analysis, *HGUGM* Hospital General Universitario Gregorio Marañón, Madrid, *STOP* Suicidality: Treatment Occurring in Paediatrics

Informed assent/consent was obtained from participants and/or their legal representatives, according to the ethical and legal standards in the participating countries. The study had approval from the Institutional Review Boards of all participating sites. Patients were recruited from the secondary/tertiary clinics from the various participatory Departments which were part of the project across the EU. The respiratory clinics from King's College Hospital, London, and Evelina London Children's Hospital contributed to the recruitment of the subjects with bronchial asthma and respiratory allergies. Those from the general population were identified through advertising on websites, schools, and libraries in the UK.

Development of the scales {#Sec3}
-------------------------

*Systematic literature review* A comprehensive and systematic literature review was performed at the outset of the study to identify the common and frequently reported risk and protective factors for suicidality in the paediatric population \[[@CR21]\]. It also considered the aspects of suicidality that were covered by the C-SSRS \[[@CR20]\] and other features relating to the revised nomenclature for the study of suicidal behaviours \[[@CR22]\].

*Selection of items and Scale development* For both the STOP-SRiFS and STOP-SReFS, three versions (Adolescent, Parent and Clinician versions) were designed based on the list of domains extracted from the systematic literature review, input from focus groups, and expert feedback. The authors followed the U.S. Food and Drug Administration (FDA) recommendations for patient outcome measure development \[[@CR23]\].

*Consumer feedback: focus groups* To explore patient's views on risk and resilience factors of suicidality, identify new items, and to verify the understanding of the items, six meetings were carried out with children, adolescents, and parents (see Fig. [1](#Fig1){ref-type="fig"}). Each group session was conducted by two clinicians and was recorded with a video camera. Notes were taken during each focus group and reviewed by the experts. Based on the focus groups, some items were simplified, re-worded using age-appropriate vocabulary, or dropped; and answer options were reduced and converted to a 4-point scoring scale.

*Expert feedback: STOP scientific advisory board* The various experts in the study and the STOP scientific advisory board reviewed the draft versions of each scale and suggested minor modifications, which were incorporated into the final versions. The final versions of the scales in English and Spanish were reviewed by a professional translator. Following this, the English versions were then translated into German, Dutch, French, and Italian, and then back-translated into English. Clinicians from each participating country in the consortium ensured that the meaning of each statement remained culturally appropriate and meaningful.

*Upload of the scales to HealthTracker*^*TM*^ Once developed, the STOP-SRiFS and STOP-SReFS scales were uploaded onto the web-based HealthTracker™ platform, an e-health platform that includes a range of different scales for monitoring physical or emotional problems \[[@CR21]\]. It was decided that the risk factors and protective factors would be presented sequentially as two scales, the STOP-Suicidality Risk Factors Scale (STOP-SRiFS) and the STOP-Suicidality Resilience Factors Scale (STOP-SReFS). At the end of this process, there are six scales; two for each different role that the scale can be assigned to/completed by. The scales are the STOP-ReFS for adolescent, parent, and clinicians, and the STOP-RiFS for adolescents, parents and clinicians.

Scoring of the scales {#Sec4}
---------------------

The focus groups and the expert panel assisted in deciding the response options to the questions and also how to score the questions.

### Scoring of the STOP-SRiFS {#Sec5}

The majority of the items in the STOP-SRiFS were single questions, except for two items ("suicide on internet", and "history of attempt") that had two sub-questions each. The item on "suicide on Internet" dealt with (1) the number of times the adolescent had looked up information about suicidal behaviours or acts described in the item; and (2) when was the last time that they had searched the internet about this. The item on "history of attempt" dealt with (1) the number of times that they had attempted suicide in the past, and (2) when was the last attempt. For these two items, the score was obtained by the sum of the two scores divided by two. The score for each STOP-SRiFS questions ranged from 0 to 4. The undefined answers ("I don't know") were coded as 888 and then substituted with an empty cell.

### Scoring of the STOP-SReFS {#Sec6}

In the STOP-SReFS, each item was composed of two sub-questions: the first one dealt with the importance the adolescent gave to the item and the second one dealt with how useful the same item was in relation to protecting them against suicidality. The score of each item is obtained by the sum of the scores of the two sub-questions divided by two. The score for the STOP-SReFS items ranged from 0 (not at all) to 4 (a great deal). The undefined answers ("I don't know") were coded as 888 and then substituted with an empty cell. Each item score was given by the sum of the two questions which composed an item divided by two.

The scales scoring method allows the presence of undefined answers when a subject who filled the scales chose "I don't know" as an answer. This was done to address the case in which the subject was unable to decide the answer, as forced answers are difficult when dealing with sensitive clinical issues such as suicidality. Little's Missing at Random Tests for all the versions of the scales which were run before the estimation of the composite scores and for single question items. The results of those analyses showed that it was not possible to impute a value for the undefined answers, and therefore, those were left as empty (not given) answers.

Phase 2: data analyses (validation of the instruments) {#Sec7}
------------------------------------------------------

Subjects completed the questionnaires online using the web-based HealthTracker™ platform. SPSS version 23 \[[@CR24]\] was used for the analyses.

*Sample 1* Consisted of 87 adolescents, their parents/carers, and clinicians from the various participating centres, who were re-administrated the scales within a maximum time of 3 weeks. This sample was used to test the time stability (test--retest reliability) of all versions of the STOP-SRiFS and STOP-SReFS.

*Sample 2* Consisted of 259 adolescents, 213 parents of adolescents, and 254 clinicians. Completion rates varied, because an adolescent might have completed the scale but not the parent of the adolescent or the clinician (see Table [2](#Tab2){ref-type="table"}).

Construct validity using Cronbach's alpha, test--retest reliability using correlations between repeat completions within 3 weeks, inter-rater reliability through correlations between the three versions of the scales, content and concurrent validity, through comparing the scores with that of the C-SSRS, and the sub-scales were generated using the Exploratory Factor Analysis (EFA) on the Adolescent, Parent, and Clinician versions of the scales. The sample sizes for all versions of both scales were above 200 and were considered adequate for these analyses \[[@CR25]\]. The extraction method used was principal axis factoring, and Promax rotation was undertaken.

To assess the concurrent validity, the adolescent, parent, and clinician versions of the scales were correlated with the C-SSRS using Pearson's correlations. The previous studies using the C-SSRS have shown convergent and divergent validity with other multi-informant suicidal ideation and behaviour scales and high sensitivity and specificity for suicidal behaviour \[[@CR26]\].

Results {#Sec8}
=======

Sample 1 comprised of 87 adolescents (mean age of 15.66 ± 1.66; 41.4% males and 58.6% females) (see Table [1](#Tab1){ref-type="table"} for the characteristics of Sample 1). Sample 2 was primarily composed of adolescents who had been screened as having some suicidality on the STOP 4-item Suicidality Screening questionnaire \[[@CR21]\] and their parents and clinicians. The sample consisted of 259 adolescents (patient age at first assignment was 15.03 ± 1.599) who completed STOP-SRiFS and/or the STOP-SReFS scales; 213 parents (patient age at first assignment was 14.92 ± 1.797) who filled one or both of the scales; and 254 clinicians (patient age at first assignment was 15.17 ± 1.552) (see Table [2](#Tab2){ref-type="table"} for demographics of Sample 2).Table 1Description of Sample 1*Gender*Male36Female51Total87*Ethnicity*Not Set12White67Asian1Chinese2Hispanic5Total87*Language*French (France)20German (Germany)6Italian (Italy)28Spanish (Spain)33Total87Developmental range was adolescent for all. Age 15.66 ± 1.66 yearsTable 2Description of Sample 2Adolescent sampleParent sampleClinician sample*Treatment group*Aripiprazole333041Cognitive behavioural therapy414164Fluoxetine686186General population55308Montelukast824Other asthma or allergy med1031Risperidone444650Total259213254*Ethnicity*White202171196Asian1363Black768Mixed568Arabic11--Chinese221Hispanic799Gypsy222Ethnicity not set201027Total259213254*Gender*Not set--11Male948888Female165124165Total259213254VersionCompletionsAdolescent259Parent213Clinician254AdolescentParentClinicianNumber259213254Patient age at first assignment15.0314.9215.17Std. Deviation1.5991.7971.552

STOP-SRiFS {#Sec9}
----------

*Construct validity* The STOP-SRiFS Adolescent version demonstrated a good reliability (Cronbach's *α* = 0.864) (Cronbach's threshold was set at *α* \> 0.700 \[[@CR27]\]). For the Parent version of the scale, two items were excluded, because their Corrected Item-Total Correlation (CITC) was below the acceptance threshold \["Sexual Identity" (CITC = 0.056), and "Change of residence" (CITC = − 0.158)\]. After excluding these two items, the STOP-SRiFS Parent version had good Cronbach's alpha value (*α* = 0.842). Similarly, the STOP-SRiFS Clinician version showed a good Cronbach's alpha (*α* = 0.722) when four items were excluded \[chronic physical illness (CITC = − 0.066), being bullied (CITC = − 0.072), use of drugs (CITC = 0.122), and change of residence (CITC = 0.045)\] (Table [3](#Tab3){ref-type="table"}).Table 3Cronbach's alpha values for STOP-SRiFs and STOP-SReFS scalesAdolescent sampleParent sampleClinician sample*Cronbach's alpha*STOP-SRiFS0.8640.8420.722STOP-SReFS0.7750.8080.808*Test*--*retest reliability* The results showed that there was good temporal stability (test--retest reliability), through the intra-class correlation coefficients between the STOP-SRiFS sub-scales scores at the first and second administration (within 3 weeks \~ 19 Days). All the intra-class correlations were good (\> 0.600) (see Table [4](#Tab4){ref-type="table"}).Table 4Intraclass correlation coefficients from the STOP-SRiFS and STOP-SReFSAdolescentParentClinician*Intraclass correlation coefficient (STOP-SRiFS)*Anxiety and depression risk0.8790.9330.884Substance misuse risk0.9320.9800.901Interpersonal risk0.7330.6060.961Chronic risk0.7360.6110.842Risk due to life events0.8770.9090.943*Intraclass correlation coefficient (STOP-SReFS)*Cognitive resilience0.8460.5470.866Interpersonal resilience0.8140.7640.882*Inter*-*rater reliability* Table [5](#Tab5){ref-type="table"} presents the inter-version correlations between the different STOP-SRiFS sub-scales for the adolescent, parent, and clinician versions, and shows that they were good (Pearson's correlation coefficient threshold was set at *r *\> 0.200 \[[@CR27]\]).Table 5Inter-version correlation coefficients from the STOP-SReFS and the STOP-SRiFS sub-scalesAdolescentParentClinician*Inter-version correlations for STOP-SRiFS*Anxiety and depression risk sub-scale Adolescent10.537\*\*0.643\*\* Parent0.537\*\*10.444\*\* Clinician0.643\*\*0.444\*\*1Substance misuse risk sub-scale Adolescent10.813\*\*0.837\*\* Parent0.813\*\*10.781\*\* Clinician0.837\*\*0.781\*\*1Interpersonal risk sub-scale  Adolescent10.548\*\*0.649\*\* Parent0.548\*\*10.490\*\* Clinician0.649\*\*0.490\*\*1Chronic risk sub-scale  Adolescent10.314\*\*0.469\*\* Parent0.314\*\*10.090 Clinician0.469\*\*0.0901Risk due to life events sub-scale Adolescent10.197\*0.136 Parent0.197\*10.044 Clinician0.1360.0441*Inter-version correlations for STOP-SReFS*Cognitive resilience sub-scale Adolescent10.1050.623\*\* Parent0.1051− 0.035 Clinician0.623\*\*− 0.0351Interpersonal resilience sub-scale Adolescent1− 0.1160.574\*\* Parent− 0.11610.159 Clinician0.574\*\*0.1591\*Correlation is significant at the 0.05 level (two-tailed)\*\*Correlation is significant at the 0.01 level (two-tailed)*Exploratory factor analysis* The items that showed poor-corrected item-total correlation (CITC) for the Parent and Clinician versions of the scale were also excluded by the EFA and, therefore, from any subsequent psychometric analysis. The experts in childhood suicidality who reviewed these results recommended that the aforementioned items, given their clinical relevance, should continue to be administered at the end of the scale as extra items, which will not be used in the scoring of the scales. As shown in Table [6](#Tab6){ref-type="table"}, EFA for the Adolescent version of the STOP-SRiFS (consisting 21 risk factor domains), a 5-factor model was determined to best fit the data based on the screen plot. The Kaiser--Meyer--Olikin (KMO) was 0.816 (*X*^2^ = 1787.257; Bartlett's test of sphericity *p* ≤ 0.001; *df* = 210). The Parent version of the scale without the two items excluded based on the Corrected Item-Total Correlation showed again that the best model to explain the structure of the scale is again a 5-factor model. The KMO was 0.720 (*X*^2^ = 727.698; Bartlett's test of sphericity *p* ≤ 0.001, *df* = 171). The results of the EFA for the parent version of the STOP-SRiFS showed that the item about the 'misuse of other drugs' had the highest loading on the factor which assessed the sub-domains concerning risk due to life events (0.216). The second highest loading for this item (0.179) was on the factor which assessed the sub-domains concerning substance misuse risk. Based on the clinical judgment of experts in child and adolescent mental health, it was decided that it was clinically relevant for this item to be part of the factor about substance misuse risk (see Table [6](#Tab6){ref-type="table"} for more details about the STOP-SRiFS factor structure). The Clinician version of the scale (5 factors) also presented with a KMO of 0.772 (*X*^2^ = 895.861; Bartlett's test of sphericity *p* ≤ 0.001, *df* = 136). Based on the pattern of risk factors domain loading, the five factors were named as: (1) anxiety and depression risk, (2) substance misuse risk, (3) interpersonal risk, (4) chronic risk, and (5) risk due to life events. These factors capture the clinical risk clusters in adolescents with suicidal ideations or behaviours.Table 6Exploratory factor analysis for the adolescent, parent, and clinician version of the STOP-SRiFS and STOP-SReFSSTOP-SRiFSAnxiety and depression riskSubstance misuse riskInterpersonal riskChronic riskRisk due to life events*Adolescent*Depressive thinking**0.960**− 0.076− 0.0110.001− 0.057Pessimism**0.928**0.0070.028− 0.091− 0.003Low self-esteem**0.905**0.0090.017− 0.1260.080Depressive mood**0.850**0.0270.0200.027− 0.090Anxiety**0.780**0.036− 0.0750.139− 0.015Worrying about school performance**0.472**0.0360.1270.0260.091Misuse of Cannabis0.000**0.881**− 0.027− 0.039− 0.087Smoking0.073**0.810**− 0.0960.0660.019Exaggerated use of alcohol− 0.002**0.598**0.076− 0.1700.092Misuse of other drugs− 0.025**0.396**0.019− 0.0280.088Relationship breakup− 0.090**0.3450.318**0.187− 0.132Searching Internet sites about suicide0.140− 0.035**0.815**− 0.154− 0.056History of suicidal attempt− 0.0320.024**0.713**0.131− 0.026Bullying0.133− 0.115**0.247**0.1370.128Discomfort with sexual identity− 0.0120.093**0.231**− 0.0930.221Chronic physical condition that produces discomfort0.006− 0.100− 0.123**0.581**− 0.038Presence of chronic pain0.079− 0.0970.135**0.527**− 0.019Preoccupation about death of close one− 0.1350.0910.049**0.368**0.126Presence of problems at home0.2810.1030.014**0.301**0.197Change of residence− 0.065− 0.0110.040− 0.010**0.759**History of completed suicide in the family0.0990.061− 0.1510.088**0.350***Parent*Pessimism**0.923**− 0.1420.051− 0.022− 0.106Depressive mood**0.863**0.0390.0020.004− 0.027Low self-esteem**0.847**0.0130.058− 0.0340.065Anxiety**0.830**0.052− 0.016− 0.017− 0.015Depressive thinking**0.677**− 0.0510.0570.1570.227Worrying about school performance**0.266**0.0430.2190.0730.061Misuse of cannabis0.043**0.911**− 0.069− 0.1510.031Smoking0.071**0.638**0.0580.1220.033Exaggerated use of alcohol− 0.278**0.411**0.2210.169− 0.024Presence of chronic pain0.101− 0.003**0.708**0.110− 0.207Chronic physical condition that produces discomfort0.0890.081**0.588**− 0.223− 0.110Searching Internet sites about suicide0.039− 0.0150.007**0.795**− 0.076History of suicidal attempt0.2110.1900.015**0.430**0.013Presence of problems at home− 0.0120.0000.210− 0.266**0.735**Relationship breakup− 0.066− 0.0270.3220.175**0.399**Preoccupation about death of close one− 0.067− 0.054− 0.1750.268**0.393**History of completed suicide in the family0.1310.038− 0.235− 0.088**0.327**Bullying0.2260.001− 0.1530.183**0.230**Misuse of other drugs0.038**0.179**− 0.1450.0560.216*Clinician*Depressive Thinking**0.896**− 0.0710.128− 0.104− 0.047Pessimism**0.830**0.079− 0.074− 0.017− 0.072Low self-esteem**0.759**0.053− 0.183− 0.0130.038Depressive mood**0.754**0.0550.0570.064− 0.136Anxiety**0.521**− 0.1260.0090.0370.358Misuse of cannabis0.031**0.823**− 0.0500.0120.025Smoking0.072**0.780**− 0.120− 0.0290.118Exaggerated use of alcohol− 0.035**0.662**0.146− 0.0620.025History of suicidal attempt− 0.019− 0.027**0.578**− 0.0550.052Discomfort with sexual identity− 0.083− 0.011**0.392**− 0.0780.080Searching Internet sites about suicide0.2090.063**0.286**0.202− 0.032Presence of problems at home0.065− 0.028− 0.149**0.521**− 0.065Presence of chronic pain− 0.093− 0.0640.012**0.346**0.004Relationship breakup− 0.0560.2310.158**0.309**− 0.016History of completed suicide in the family0.0210.1600.121− 0.187**0.357**Preoccupation about death of close one− 0.1940.119− 0.0010.123**0.341**Worrying about school performance0.175− 0.0680.0480.173**0.289**STOP-SReFSInterpersonal resilienceCognitive resilience*Adolescent*Friendships**0.787**− 0.135Optimism**0.672**0.070Hobbies**0.606**− 0.022Internal control**0.476**0.017Empathy**0.407**0.271Religious beliefs**0.234**0.075Family connectiveness− 0.144**0.920**Social environment0.373**0.488**External control0.028**0.217***Parent*Social environment**1.063**− 0.133Family connectiveness**0.505**0.272Internal control**0.335**0.119Empathy− 0.030**0.788**Optimism0.080**0.634**Friendships0.254**0.438**Religious beliefs− 0.022**0.334**External control0.083**0.331**Hobbies0.275**0.321***Clinician*Social environment− 0.146**0.992**Family connectiveness− 0.087**0.743**Friendships0.196**0.509**Hobbies0.191**0.487**Empathy0.281**0.460**External control0.049**0.335**Optimism**0.808**0.010Religious beliefs**0.445**0.021Internal control**0.423**− 0.030Extraction method: principal axis factoring, and promax rotationNumbers in bold indicate the item that the factor belongs to*Content validity* As predicted, the correlations between the sub-scales of STOP-SRiFS adolescent version and the C-SSRS total score were significant, indicating that increased risk was associated with increased C-SSRS total score (Table [7](#Tab7){ref-type="table"}). Broadly speaking, the STOP-SRiFS sub-scale scores in the parent and clinician versions were similarly correlated with the C-SSRS total score. The sub-scale scores that did not reach significance were those which would be rated differently by the parents and clinicians in comparison to the adolescent (Table [7](#Tab7){ref-type="table"}).Table 7Correlations between STOP-SReFS and STOP-SRiFS sub-scales, and the C-SSRS total scoreAdolescentParentClinician*Columbia-suicide severity rating scale correlations*STOP-cognitive resilience sub-scale− 0.275\*\*− 0.070− 0.143\*STOP-interpersonal resilience sub-scale− 0.117− 0.132− 0.046STOP-anxiety and depression risk sub-scale0.610\*\*0.426\*\*0.497\*\*STOP-substance misuse risk sub-scale0.221\*\*0.1030.097STOP-interpersonal risk sub-scale0.491\*\*0.450\*\*0.472\*\*STOP-chronic risk sub-scale0.287\*\*− 0.0290.153\*STOP-risk due to life events sub-scale0.0880.193\*\*0.178\*\*\*\*Correlation is significant at the 0.01 level (two-tailed)\*Correlation is significant at the 0.05 level (two-tailed)

STOP-SReFS {#Sec10}
----------

*Construct validity* The Cronbach's alpha values for all the versions of the STOP-SReFS (Adolescent: 0.775; Parent: 0.808; Clinician: 0.808) (Table [3](#Tab3){ref-type="table"}) indicate good internal consistency of the scale (Table [3](#Tab3){ref-type="table"}).*Test*--*retest reliability* The results showed a good temporal stability (test--retest reliability). This was assessed in Sample 1 through the intra-class correlation coefficients between the STOP-SReFS sub-scales scores at the first and second administration (within 3 weeks \~ 19 days). These results showed that all intra-class correlations were above the acceptance threshold (\> 0.600), except for the parent cognitive resilience scale which was below the threshold (0.547) (see Table [4](#Tab4){ref-type="table"}). This is understandable, because suicidality risk factors can change even in the short period used for the test--retest.*Inter*-*rater reliability* Table [5](#Tab5){ref-type="table"} presents the inter-version correlations between the different STOP-SRiFS and STOP-SReFS sub-scales for the Adolescent, Parent, and Clinician versions, which were all acceptable.*Exploratory factor analysis* As shown in Table [6](#Tab6){ref-type="table"}, EFA for the Adolescent version of the STOP-SReFS identified that a two-factor model was the best fit (the KMO was 0.769 (*X*^2^ = 511.748; Bartlett's test of sphericity *p* ≤ 0.001, *df* = 36). The EFA of the STOP-SReFS Parent version also showed that the best model to explain the structure of the scale was a two-factor model (the KMO was 0.819 (*X*^2^ = 446.362; Bartlett's test of sphericity *p* ≤ 0.001, *df* = 36). The EFA of the STOP-SReFS Clinician version was similar and had a KMO of 0.813 (*X*^2^ = 572.156; Bartlett's test of sphericity *p* ≤ 0.001, *df* = 36). Based on the pattern of resilience factors domain loading, the two factors were named: (1) interpersonal resilience and (2) cognitive resilience. These resilience factors are in keeping with known protective factors. The EFA revealed that the scales were not unidimensional and, therefore, precludes the use of a total score. In view of this, correlations between the STOP-SReFS sub-scales and their correlations with the C-SSRS total score were performed.*Content validity* Correlations between the STOP-SRiFS and STOP-SReFS sub-scales, and the C-SSRS total score are presented in Table [7](#Tab7){ref-type="table"}. As expected, the C-SSRS negatively correlated with the STOP-SReFS (captures protective factors) cognitive resilience sub-scale for the adolescent (*r* = − 0.275). However, the clinician (*r* = − 0.143) versions of the scale did not meet the threshold of *r* \> 0.200 \[[@CR26]\] (Table [7](#Tab7){ref-type="table"}). The STOP-SReFS Interpersonal resilience sub-scale correlations were all negative, but none of them were significantly different to the C-SSRS total scores for either the adolescent, parent, or clinician versions of the scales.

Discussion {#Sec11}
==========

Despite progress made in suicidality research, the risk and resilience factors involved in suicidal behaviour and ideation remain poorly understood. The present study describes the development and the subsequent psychometric validation of two scales: the STOP-Suicidality Risk Factors Scale (STOP-SRiFS) and the STOP-Suicidality Resilience Factors Scale (STOP-SReFS)---two web-based instruments that measure elements of suicidality on the web-based HealthTracker™ system. The measurement properties of the two instruments were assessed using the consensus-based standards for the selection of health status Measurement instruments (COSMIN) \[[@CR28]\]. The COSMIN checklist was used to structure the layout of the manuscript when reporting a study describing psychometric instruments. Using this approach, the psychometric analyses revealed that the STOP-SReFS and the STOP-SRiFS were reliable and valid instruments for assessing suicidality risk and resilience factors in adolescents. The fact that the STOP-SRiFS and the STOP-SReFS are more age-specific scales, which have been designed and worded specifically for the adolescent population, and that they can be completed online, decreasing completion time and ensuring accessibility at all times, increases their potential applicability in an adolescent population \[[@CR29]\]. As suicidal behaviour depends on diverse clinical, psychological, sociological, and biological factors, the consensus is that a multi-informant evaluation is strongly recommended \[[@CR21]\]. Furthermore, adolescents who are a particularly high-risk group for suicidality differ from the adult population and need a deeper, wider, and multi-dimensional approach \[[@CR30]\]. The study of cross-informant agreement has been shown to be useful in obtaining a more detailed understanding of the adolescent population \[[@CR31]\] as they usually tend to not report the same information as their parents, teachers, or clinicians. In this study, results in adolescents and parents showed a good correlation, contrary to some studies that report low agreement between parents and adolescents \[[@CR32]\].

The threshold for the minimum loading for EFA was set at \> 0.200. Thresholds in the region of \> 0.200 have been cited in the literature \[[@CR33], [@CR34]\] and we have previously used a similar threshold for factor loading to validate and assess the psychometric properties of a parent version of a neuropsychiatric scale \[[@CR35]\]. In the context of the present study, we set a threshold of \> 0.200 so that the factor loading would best reflect the phenomenon of interest in accordance with our sample size, clinical judgement, and exploratory nature of the study.

Suicide risk factors have been widely studied, whilst the study of protective factors has been usually neglected. However, in the past years, there has been an increasing interest in incorporating the concept of resilience into the suicidality paradigm \[[@CR36]\]. The identification of specific risk and resilience factors in young people could help to develop personalized therapeutic strategies, in which treatment is tailored to the personal needs of each patient. In addition, this could lead to the development of targeted interventions for some of these risk and/or resilience factors, for example, intervention programs aimed at improving the family connectedness. This knowledge may lead to actions and changes which can have an impact on the suicide rates as shown in the Youth Aware of Mental Health Programme (YAM), a manualized, universal school-based intervention which has shown efficacy in reducing the number of suicide attempts and severe suicidal ideation in adolescents \[[@CR16]\]. The SEYLE trial, which has been recruiting a large number of European adolescents, has also addressed these issues, concluding that screening is an efficient method to refer subjects in need of treatment \[[@CR16]\].

The Internet has become a public and accessible information exchange forum for individuals. The use of new technologies could innovate healthcare, i.e., a web-based version of a questionnaire may enhance perceptions of privacy and confidentiality, which may improve honesty of responses, particularly when less socially desirable, especially to those items related to emotions \[[@CR37]\].

As far as we are aware of, this is the first attempt to assess risk and resilience factors related to suicidality in the adolescent population using web-based measures, and accounting for different sources of information. The thorough methodology employed, the sample size, the focus groups in which all interested parties were involved in co-designing the scales, the external scientific supervision by experts in the field, and its applicability to multiple pathologies and settings offered added value to this study.

Limitations {#Sec12}
===========

There are limitations to this study that need to be considered. To identify subjects at risk, a positive and undefined answer to the screening questionnaire of the STOP-Suicidality Assessment Scale (STOP-SAS) \[[@CR21]\] was necessary for patients to be allocated the full STOP-SRiFS and STOP-SReFS. Since the aim of the study was to develop a universal instrument, we did not account for the effect of diagnosis and sex on these risk and protective factors. Moreover, not being able to substitute the missing values in the database with estimations led to a reduced sample size.

Conclusion {#Sec13}
==========

The current study suggests that the STOP-SRiFS and the STOP-SReFS scales are viable instruments to assess risk and resilience factors in young people. They can be used to identify subgroups in the adolescent population who may need targeted intervention. In this vein, the STOP-SRiFS and the STOP-SReFS could be used as effective risk stratification tools to provide a multi-informant view on adolescent risk for suicidality and maybe of value for the assessment of suicidality in clinical trials. This sentiment has been echoed by others, who have highlighted the need for improving the detection and assessment of suicidality in clinical trials \[[@CR38]\]. Moreover, the identification of subpopulations with a personalized level of specific risk and protective factors could guide personalized interventions, which ultimately may help to reduce suicide rates and improve prognosis in paediatric populations.
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